H.R. 1222 would direct the Secretary of Health and Human Services (HHS), through the Centers for Disease Control and Prevention (CDC), to enhance surveillance capabilities to track the epidemiology of congenital heart disease (CHD) and to provide grants to study the epidemiology of CHD across the lifespan. In addition, the legislation would require the Secretary to produce a report to Congress on CHD that includes information on the demographics and health care utilization of individuals with the disease. H.R. 1222 would authorize the appropriation of a total of $20 million for fiscal years 2018 through 2022 to carry out those activities. Additionally, the bill would reauthorize research on CHD at the National Institutes of Health (NIH) and would require NIH to produce a report on its research efforts on CHD. CBO estimates that implementing all the provisions in H.R. 1222 would cost $131 million over the 2018-2022 period, assuming appropriation of the necessary and specified amounts. Pay-as-you-go procedures do not apply to this legislation because it would not affect direct spending or revenues.
CBO estimates that enacting H.R. 1222 would not increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2028.
H.R. 1222 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act and would impose no costs on state, local, or tribal governments.